The new data on prostate cancer screening: What should we do now?

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 8, 2009, Pages 446-448

  Gilligan, Timothy ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CANCER DIAGNOSIS; HUMAN; MALE; MASS SCREENING; METHODOLOGY; NOTE; PROSTATE TUMOR; UTILIZATION REVIEW;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 70350464294     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.09079     Document Type: Editorial

References (8)

1. Klein E. What's new in prostate cancer screening and prevention? Cleve Clin J Med 2009; 76:439-445.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
3. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
4. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995. Bethesda, MD: National Cancer Institute; 1999.
5. Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
6. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8:439-443.
7. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
8. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007; 4:692-698.